Adicet Bio Inc (ACET)
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. Its lead candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy engineered with a CAR that targets CD20 and is being studied for potential use in autoimmune diseases. The company is also advancing ADI-212, a gene-edited, armored clinical candidate designed to target prostate-specific membrane antigen. Founded in 2014, Adicet Bio is based in Boston, Massachusetts. The company’s common stock is listed on NASDAQ under the ticker ACET.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACET
|
$11.44
|
25.1% Upside
|
Undervalued
|
$33.17
|
262.7% Upside
|
Bargain
|
Fair
|
0.0%
|
November 11, 2026
|
0.8x
|
98.44 M
|
-9.211 M
|
11.3%
|
69.1%
|
-6.8
|
85.8%
|
